Umabs DB is currently the most comprehensive global database for antibody drugs, recording nearly 10,000 antibody drugs from clinical trials to commercialization, covering over 1,600 targets and more than 2,400 disease types, with 2,900+ research institutions involved, encompassing various professional information such as drug protein sequences, patents, and clinical data. The Umabs DB drug database … Read more
In 2024, the global antibody drug market is expected to experience explosive growth. According to IQVIA, global spending on biopharmaceuticals is projected to exceed $892 billion by 2028, with antibody drugs holding a significant share. In the fields of oncology and autoimmune diseases, three major technological routes—bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and proteolysis-targeting chimeras … Read more
Introduction Degrader-Antibody Conjugates (DAC) are a novel entity that combines the payload of Protein Degradation Targeting Chimeras (PROTAC) with monoclonal antibodies through a type of chemical linker (DAC =PROTAC + ADC). This article collects several examples of DAC from scientific and patent literature and documents specific challenges associated with DAC construction. Overall, these examples indicate … Read more
Currently, there are 15 ADC drugs approved globally, among which 6 ADC drugs have been approved in China, namely Trastuzumab emtansine, Brentuximab vedotin, Trastuzumab deruxtecan, Vidofludimus, Gemtuzumab ozogamicin, and Sacituzumab govitecan. This article provides a brief summary based on the currently approved ADC drugs worldwide, the types of tumors they are suitable for, and how … Read more